Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7712 pages
Showing 1051 - 1100Meta-Analysis of Outcomes With Anthracycline-Containing and Taxane-Containing Chemotherapy in Early-Stage Breast Cancer
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), a patient-level meta-analysis showed that anthracycline/taxane regimens were associated with better outcomes compared with regimens excluding either drug class in patients with early-stage operable breast...
Subcutaneous vs Intravenous Rituximab in First-Line Treatment of Low–Tumor Burden Follicular Lymphoma
In a French phase III trial (FLIRT) reported in the Journal of Clinical Oncology, Cartron et al found that the use of subcutaneous (SC) vs intravenous (IV) rituximab was associated with improved progression-free survival in the first-line treatment of low–tumor burden follicular lymphoma. Study...
Adjuvant Chemotherapy After Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Mileshkin et al, the phase III OUTBACK trial has shown no survival benefit with adjuvant carboplatin/paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy as primary treatment in patients with locally advanced cervical cancer. Study...
Response Assessment in Neuro-Oncology Criteria in Determining Correlation of Survival Outcomes in Glioblastoma
In a study reported in the Journal of Clinical Oncology, Youssef et al found that the standard Response Assessment in Neuro-Oncology (RANO) and modified RANO (mRANO) criteria produced similar correlations between progression-free survival and overall survival in newly diagnosed glioblastoma and...
Updated Findings From JAVELIN Bladder 100 Trial of Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma
An updated analysis of the phase III JAVELIN Bladder 100 trial continued to show benefits in overall survival and progression-free survival with avelumab maintenance plus best supportive care vs best supportive care alone in patients with advanced urothelial carcinoma who were progression-free...
Long-Term Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar vs Reference Trastuzumab in HER2-Positive Early Breast Cancer
In a secondary analysis of the phase III SB3-G31-BC trial, Pivot et al found that perioperative use of the trastuzumab biosimilar SB3 was associated with a similar cardiac safety profile and similar efficacy outcomes compared with reference trastuzumab after up to 6 years of follow-up in patients...
Trastuzumab Deruxtecan vs Physician’s Choice in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine
As reported in The Lancet by André et al, the phase III DESTINY-Breast02 trial has shown improved progression-free survival with fam-trastuzumab deruxtecan-nxki vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received prior ado-trastuzumab...
Second-Line Liposomal Irinotecan Plus Fluorouracil/Leucovorin in Metastatic Biliary Tract Cancer
In an updated analysis of a Korean phase IIb trial (NIFTY) reported in JAMA Oncology, Hyung et al found that the addition of nanoliposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival in patients with metastatic biliary tract cancer with disease...
Financial Impact on Caregivers of Spouses With Cancer
In a study reported in the Journal of Clinical Oncology, Bradley et al found that approximately one-third of caregivers of spouses with cancer reported they had stopped working and had increased household debt. In the subgroup with a lower-than-median household income, cancer caregivers were more...
Study Investigates Prevalence of ‘Low-Value’ PSA Screening for Prostate Cancer in Older Patients
In a survey study reported in JAMA Network Open, Kalavacherla et al found a high prevalence of prostate-specific antigen (PSA) screening for prostate cancer among older patients than recommended for such screening in U.S. Preventive Services Task Force guidelines. The investigators stated: “The...
Dabrafenib With Trametinib for Pediatric Low-Grade Glioma With BRAF V600E Mutation
On March 16, 2023, dabrafenib with trametinib was approved for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.1,2 The U.S. Food and Drug Administration also approved new oral formulations of both drugs suitable for patients who ...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
Racial/Ethnic Disparities in Locoregional Recurrence Among Patients With Breast Cancer Treated in the TAILORx Trial
In a retrospective post hoc analysis reported in JAMA Surgery, Olga Kantor, MD, and colleagues found that locoregional recurrence was more common among Black and Asian vs White patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer in the context of similar access...
Association of Delayed or Foregone Care Among Patients With Cancer and Patient-Clinician Identity Discordance
In a study reported in a research letter in JAMA Oncology, Patel et al found that delayed or foregone care due to patient-clinician discordance of identity (eg, race, religion, gender) was more common among patients with cancer vs noncancer controls. Approximately one-quarter of younger patients...
Sugemalimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma
In a Chinese phase II study (GEMSTONE-201) reported in the Journal of Clinical Oncology, Huang et al found that the PD-L1 inhibitor sugemalimab produced durable responses in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma. Study Details In the multicenter trial, 78...
Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Susan Halabi, PhD, and colleagues validated an overall survival prognostic model for docetaxel-naive patients with metastatic castration-resistant prostate cancer. As noted by the investigators, “We have previously developed and externally...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancers
In a single-institution study reported in JACC: CardioOncology, Feldman et al found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespective of tumor type. Study Details The retrospective cohort study used...
Long-Term Survival in Patients Diagnosed With Cancer During Pregnancy or Postpartum
In a Canadian population–based retrospective cohort study reported in JAMA Oncology, Cairncross et al found that patients diagnosed with cancer during pregnancy or postpartum had worse 5-year survival than those diagnosed at a time remote from pregnancy. Study Details The study included data from...
Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
In a phase II study reported in a research letter in JAMA Oncology, Agrawal et al found that a single treatment with psilocybin (COMP360) with a 1:1 therapist-to-patient ratio reduced symptoms of depression in patients with cancer and major depression disorder treated at a single community cancer...
Preoperative Peritumoral Infiltration of Local Anesthetic in Patients With Early Breast Cancer: Effect on Survival
In an Indian trial reported in the Journal of Clinical Oncology, Badwe et al found that peritumoral infiltration of local anesthetic prior to surgery in patients with early breast cancer was associated with improved disease-free and overall survival. As stated by the investigators, “Preventing...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
MRD and KMT2A Fusion Partners in Predicting Outcomes of Childhood KMT2A-Rearranged Acute Myeloid Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, van Weelderen et al, of the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG), found that KMT2A fusion partners and measurable residual disease (MRD) at end of induction phase 2 were independent predictors of...
Addition of Abiraterone Acetate and Prednisone to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, and colleagues, the phase III Alliance A031201 trial has shown no significant improvement in overall survival with the addition of abiraterone acetate and prednisone to enzalutamide as first-line treatment for metastatic...
Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...
Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors
In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase inhibitor cabozantinib showed promising activity in patients with advanced clear cell renal cell...
Confirmatory Mediastinoscopy vs Immediate Resection After Endosonography for Resectable NSCLC
In a trial (MEDIASTrial) reported in the Journal of Clinical Oncology, Bousema et al found that immediate lung tumor resection after negative systematic endosonography was noninferior to confirmatory mediastinoscopy in the detection of unforeseen N2 disease in patients with non–small cell lung...
Addition of Ipilimumab to Nivolumab in Recurrent or Metastatic Head and Neck Cancer
As reported in JAMA Oncology by Kevin J. Harrington, MBBS, PhD, and colleagues, the phase II CheckMate 714 trial has shown that the addition of ipilimumab to nivolumab did not improve objective response rate as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of ...
Consensus Molecular Subtypes as Markers for Maintenance Therapy Regimens for RAS Wild-Type Metastatic Colorectal Cancer
In an analysis of the German phase II PanaMa trial reported in the Journal of Clinical Oncology, Stahler et al evaluated consensus molecular subtypes as prognostic and predictive biomarkers in patients with RAS wild-type metastatic colorectal cancer receiving fluorouracil and leucovorin with or...
GD2-CAR T Cells for Relapsed or Refractory High-Risk Neuroblastoma
In a single-institution Italian phase I/II trial reported in The New England Journal of Medicine, Del Bufalo et al found that treatment with chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2 expressed on tumor cells (GD2-CART01) produced responses in pediatric patients...
Pathologic Complete Response as Surrogate for Event-Free and Overall Survival in Neoadjuvant Trials in HER2-Positive Early Breast Cancer
In a study reported in the Journal of Clinical Oncology, Squifflet et al found that pathologic complete response (pCR) was a weak surrogate for event-free and overall survival in neoadjuvant trials of anti-HER2 therapy in patients with HER2-positive early breast cancer. Study Details In the study,...
Mortality After Colonoscopy-Detected vs Postcolonoscopy-Diagnosed Colorectal Cancer in the VA Health-Care System
In a study reported in JAMA Network Open, Kahi et al found no differences in all-cause or cancer-specific mortality among veterans in the Veterans Affairs (VA) health-care system with colonoscopy-detected colorectal cancer vs those with postcolonoscopy-diagnosed colorectal cancer. Study Details...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Olanzapine to Prevent Chemotherapy-Related Anorexia in Newly Diagnosed Patients With Advanced Cancers
In an Indian single-center study reported in the Journal of Clinical Oncology, Sandhya et al found that olanzapine was associated with weight gain and improved appetite vs placebo in patients receiving chemotherapy for newly diagnosed locally advanced or metastatic gastric,...
T-DXd in HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
In a Japanese phase II trial (STATICE) reported in the Journal of Clinical Oncology, Nishikawa et al found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed activity in patients with HER2-expressing advanced or recurrent uterine carcinosarcoma. Study Details In the multicenter trial, 32 evaluable ...
Interaction of H pylori Infection and Germline Pathogenic Variants in Risk for Gastric Cancer
In a Japanese study reported in The New England Journal of Medicine, Usui et al found that Helicobacter pylori infection affected the risk of gastric cancer in patients with predisposing germline pathogenic variants, including variants in homologous recombination genes. As stated by the...
Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer
On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...
Effect of Smoking Cessation After Diagnosis of Renal Cell Carcinoma on Disease Progression and Survival Outcomes
In a Russian single-institution prospective cohort study reported in the Journal of Clinical Oncology, Sheikh et al found that quitting smoking after a diagnosis of renal cell carcinoma (RCC) was associated with improved disease progression and survival outcomes among patients. Study Details The...
Primary Overall Survival Analysis of the ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Christopher J. Sweeney, MBBS, and colleagues, the primary overall survival analysis of the phase III ENZAMET trial showed a significant benefit with enzalutamide plus testosterone suppression vs standard nonsteroidal antiandrogen treatment plus testosterone...
Addition of Toripalimab to Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
In a Chinese single-center phase II trial (EC-CRT-001) reported in The Lancet Oncology, Zhu et al found that the addition of the PD-1 inhibitor toripalimab to definitive chemoradiotherapy resulted in “encouraging activity and acceptable toxicity” in patients with locally advanced esophageal...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Julie E. Bauman, MD, MPH, and colleagues found that the combination of the antihepatocyte growth factor antibody ficlatuzumab and cetuximab was active in patients with cetuximab-resistant, recurrent or metastatic head and neck...
Addition of Niraparib to Abiraterone Acetate and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, and colleagues, the phase III MAGNITUDE trial showed that the addition of niraparib to abiraterone acetate and prednisone improved radiographic progression–free survival as first-line treatment in patients with metastatic...
Addition of Bortezomib to R-CHOP in Patients With DLBCL According to Molecular Subgroups: 5-Year Follow-up of the REMoDL-B Study
In a 5-year analysis of the UK/Swiss phase III REMoDL-B trial reported in the Journal of Clinical Oncology, Davies et al found that the addition of bortezomib to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RB-CHOP) as initial treatment was associated with...
Prognostic Performance of a Molecular International Prognostic Scoring System for MDS
In a European study reported in the Journal of Clinical Oncology, Sauta et al found that the recently devised Molecular International Prognostic Scoring System (IPSS-M) had improved prognostic ability vs the standard Revised International Prognostic Scoring System (IPSS-R) in patients with...
Hypercalcemia in Patients With Cholangiocarcinoma
In a study reported in a research letter in JAMA Oncology, Konstantinidou et al found that the prevalence of hypercalcemia increased over time in patients with cholangiocarcinoma and was significantly more common in those with IDH1-mutant intrahepatic disease. Study Details The study involved...
Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer
In a study reported in JAMA Network Open, Holt et al found that health insurance status was a substantial mediator in the diagnosis of advanced-stage vs early-stage cervical cancer across ethnicity and race in patients from the United States. Study Details The retrospective, cross-sectional,...
Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer
In a Swedish case-cohort study reported in the Journal of Clinical Oncology, Eriksson et al found that an image-based short-term risk model outperformed a traditional lifestyle/familial risk–based risk model in predicting the likelihood of development of breast cancer over a 10-year period. Study...
How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?
In a study reported in the Journal of Clinical Oncology, Sarfaty et al identified novel genetic subtypes of urothelial carcinoma exhibiting different responses to immune checkpoint blockade. Study Details In the multicenter study, whole-exome sequencing was performed on tumor specimens from 88...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
